DexCom price target raised to $134 from $132 at BTIG

BTIG analyst Marie Thibault raised the firm’s price target on DexCom to $134 from $132 and keeps a Buy rating on the shares. Q1 results highlighted the company’s strong quarter and the management’s tone was upbeat on the early U.S. G7 launch, the interest in basal-only CGM, and adoption via Dexcom ONE, the analyst tells investors in a research note. The increase in 2023 revenue guidance is also "conservative" and a "prudent approach" early in the year, BTIG added.